Genfit's results are very mixed, but the trial failed without massaging the data. I'm out. I took a hit, although I got out by getting the news via Twitter before US investors, so I only took half of the drop.
I second the congrats on CNAT - I had it and let it go. May buy it back. I still have Genfit. That's a binary event coming up any day.
fininsun, mrk's drugs will be DOA. The market (i.e. the payers) wants something better if it's going to replace Harvoni. They want 6 and 8 week therapies, or even 4 week. One or possibly two combo pills. They want Achillion.
I'm with you Charles - this took me by surprise. However, I doubled my position. #$%$ far as the biotech sector goes, I'm not sure if we are in the first third of a 20%+ correction, or just another hiccup. I suspect the latter.
no particular reason other than its a conference and it's BLUE out there talking. Last public comment on SCD was Dec 9 that the SCD patient achieved neutrophil engraftment. We are now another 3-4 months out and so I'm thinking they may make a comment about how the patient is doing, without having any conclusions yet.
thanks Magnam! I have to admit, I haven't done full DD on Esperion, other than looking at the data from last trial. I bought today purely because of the $15 drop to $87. It might drop to $80-84, in which case I may buy more.
last four trading days are higher than average volume. Today is 233% of average volume. We may have a bit more to go but tomorrow it could snap back just as easily...
big blood bath. Ironically, not so much in ACHN. I picked up some ESPR shares when they retraced 50% to $87. Now that all the green I have on the board today!
"denotes your Lack of Integrity or knowledge on this Field of Medicine."
Say what mac? pokey has a lack of integrity because he stated a legitimate fact about business executives in developing companies? Seriously? And he has lack of knowledge on [sic] this "Field of Medicine"? What field would that be mac, virology? You mean the one about which you have expressed endless scientific knowledge? Damn you can be annoying. #$%$!
Hi- did you buy? If it does another nosedive premarket I would get in then. It should build until June. One thing that I don't think was talked about much on this board was how advanced the patients were. This was stage 3-4 RCC. A few months of life left to a year or so. I still am at a loss as to why drugs are often tested first on these extremely hard to treat patients. For compassionate use, yes, but not for rigorous efficacy testing!
I took care of that problem Clutch! When GILD announced their "safety warning" I bought it a few bucks cheaper. Now I own both again - ACHN and GILD.
Charles, I don't know, but what I do know is that Pfizer is holding its license to ISONEP until after the trial results are out.
the other thing to remember is that Pfizer has held off selling their interest in the ISONEP trial until after they see the results. They are divesting of ophthalmology drugs but they obviously think they will get a much higher price for their share if they wait...